The innovative monoclonal antibody, Pritoxaximab – formerly known as DXX00601 – presents remarkable opportunity for the treatment of acute hemolytic reaction (TRALI). Developed by scientists, Pritoxaximab functions https://www.targetmol.com/compound/pritoxaximab